Azacitidine: A novel agent for myelodysplastic syndromes

American Journal of Health-System Pharmacy

Volumn 62, Issue 15, 2005, Pages 1567-1573

  Sullivan, Meaghan ^a,b   Hahn, Kristine ^c   Kolesar, Jill M ^b  

^a Aurora Pharmacy   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Comprehensive Cancer Center ^*

Author keywords

Absorption; Antineoplastic agents; Azacitidine; Blood levels; Dosage; Drug administration; Mechanism of action; Myelodysplastic syndromes; Pharmacokinetics; Quality of life; Toxicity

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BIOLOGICAL RESPONSE MODIFIER; CREATININE; CYCLIN DEPENDENT KINASE; CYCLOSPORIN; CYTOCHROME P450; CYTOKINE; DEXAMETHASONE; DNA; DNA METHYLTRANSFERASE; ETANERCEPT; ETOPOSIDE; HEAVY METAL; HLA ANTIGEN; NUCLEIC ACID; ORGANIC COMPOUND; PESTICIDE; PROTEIN P15; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOID; SEROTONIN ANTAGONIST; THALIDOMIDE; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; COST CONTROL; CYTOGENETICS; CYTOTOXICITY; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; ENZYME ACTIVITY; ERYTHROCYTE TRANSFUSION; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION; KIDNEY TUBULE ACIDOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SURVIVAL; THROMBOCYTE TRANSFUSION; TUMOR SUPPRESSOR GENE; URINARY EXCRETION; VOMITING;

EID: 23044483868     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040385     Document Type: Review

References (32)

1. Silverman L, Holland JF, Frei E et al. The myelodysplastic syndrome. In: Holland JF, Frei E, eds. Cancer medicine. 5th ed. Hamilton; Ontario: B. C. Decker Inc.; 2000:1931-46.
2. National Comprehensive Cancer Network. Practice guidelines in oncology: myelodysplastic syndromes. 2004. Version.1.2005. www.nccn.org/ professionals/physician_gls/PDF/ mds.pdf (accessed 2005 Apr 22).
3. Michels SD, McKenna RW, Arthur DC et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985; 65:1364-72.
4. Dansey R. Myelodysplasia. Curr Opin Oncol. 2000; 12:13-21.
5. Koeffler HP, Golde DW. Human preleukemia. Ann Intern Med. 1980; 93:347-53.
6. Foucar K, Langdon RM II, Armitage JO et al. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer. 1985; 56:553-61.
7. Block M, Jacobson LO, Bethard WF. Preleukemic acute human leukemia. JAMA. 1953; 152:1018-28.
8. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103:620-5.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100:2292-302.
10. Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989; 74:395-408.
11. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079-88.
12. Vidaza (azacitidine) package insert. Boulder, CO: Pharmion Corporation; 2004 May.
13. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine: a new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med. 1976; 85:237-45.
14. Christman JK, Mendelsohn N, Herzog D et al. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res. 1983; 43:763-9.
15. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem. 1982; 257:2041-8.
16. Ley TJ, DeSimone J, Anagnou NP et al. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+thalassemia. N Engl J Med. 1982; 307:1469-75.
17. Kizaki M, Koeffler HP. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol. 1992; 19:95-105.
18. Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist. 2001; 6(suppl 5):8-14.
19. Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis. 2000; 21:461-7.
20. Quesnel B, Guillerm G, Vereecque R et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998; 91:2985-90.
21. INK4B gene in myelodysplastic syndromes. Blood. 1997; 90:1403-9.
22. Silverman LR, Zinar S, Holland JF. Azacytidine acts as a biologic response modifier on hematopoietic cell response to cytokines. Proc Am Assoc Cancer Res. 1998; 39:405. Abstract.
23. Troetel WM, Weiss AJ, Stambaugh JE et al. Absorption, distribution, and excretion of 5-azacytidine (NSC 102816) in man. Cancer Chemother Rep. 1972; 56: 405-11.
24. Silverman LR, Holland JF, Weinberg RS et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993; 7(suppl 1):21-9.
25. Silverman L, Holland JF, Demakos E et al. Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol. 1994; 68:abstract 12.
26. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20:2429-40.
27. Kornblith AB, Herndon JE II, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20: 2441-52.
28. Schiffer CA, Anderson K, Coleman M et al. Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacytidine administered by continuous infusion: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1985; 69:1027-8.
29. Bellet RE, Mastrangelo MJ, Engstrom PF et al. Hepatotoxicity of 5-azacytidine (NSC 102816): a clinical and pathologic study. Neoplasma. 1973; 20:303-9.
30. Red book update. Montvale, NJ: Medical Economics; 2004:10.
31. Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18:956-62.
32. Saba HI, Rosenfeld CS, Issa J et al. Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs supportive care (SC) in patients with advanced myelodysplastic syndrome (MDS). Presented at 2005 ASCO Annual Meeting. Orlando, FL; 2005 May 13-17.